Celecoxib CAS 169590-42-5 Assay 98.0~102.0%
I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi ohamba phambili we-Celecoxib (i-CAS: 169590-42-5) enomgangatho ophezulu.I-Ruifu Chemical inokubonelela ngenkonzo yehlabathi jikelele, ixabiso elikhuphisanayo, inkonzo egqwesileyo, encinci kunye nezixa ezininzi ezikhoyo.Thenga iCelecoxib,Please contact: alvin@ruifuchem.com
| Igama leMchiza | Celecoxib |
| Izithethantonye | Celebrex;Umbhiyozo;Celecox;Yonke into;Solexa;SC-58635;SC 58635;I-YM-177;4--[5-(4-Methylphenyl)-3-(Trifluoromethyl)-1H-Pyrazol-1-yl]benzenesulfonamide;5-(4-Methylphenyl)-1-(4-Sulfamoylphenyl)-3-(Trifluoromethyl)pyrazole |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoRhwebo |
| Inombolo yeCAS | 169590-42-5 |
| Ifomula yeemolekyuli | I-C17H14F3N3O2S |
| Ubunzima beMolekyuli | 381.37 g/mol |
| Indawo yokunyibilika | 160.0 ukuba 165.0℃ |
| Ukuxinana | 1.43±0.10 g/cm3 |
| Ukunyibilika kwamanzi | Ayinyibilikiyo emanzini |
| Ukunyibilika | Inyibilika kakhulu kwiMethanol;Inyibilika kwi-Ethanol |
| I-COA kunye ne-MSDS | Iyafumaneka |
| Isampulu | Iyafumaneka |
| Imvelaphi | Shanghai, China |
| Uphawu | Ruifu Chemical |
| Izinto | ImiGangatho yokuHlola | Iziphumo |
| Imbonakalo | Umgubo weCrystalline oMhlophe okanye ophantse wamhlophe | Iyahambelana |
| Isivavanyi | 98.0~102.0% | 99.8% |
| Indawo yokunyibilika | 160.0 ukuba 165.0℃ | 162.2℃ |
| Amanzi nguKarl Fischer | <0.50% | 0.11% |
| Intsalela kwi-Ignition | <0.20% | 0.05% |
| Iintsimbi ezinzima (Pb) | ≤20ppm | <10ppm |
| Celecoxib Related Compound A | <0.40% | <0.20% |
| Celecoxib Related Compound B | <0.10% | <0.10% |
| Ukungcola Okungachazwanga Ngomntu Ngamnye | <0.10% | <0.10% |
| Ukungcola okupheleleyo | <0.50% | 0.20% |
| I-Infrared Spectrum | Ngokungqinelana noLwakhiwo | Iyahambelana |
| I-1H NMR Spectrum | Ngokungqinelana noLwakhiwo | Iyahambelana |
| Ukuqukumbela | Imveliso ivavanyiwe kwaye ihambelana neenkcukacha ezinikiweyo | |
Umqulu:Ibhotile eFluorinated, iAluminium foil bag, 25kg/Cardboard Drum, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina isikhongozeli sivalwe ngokuqinileyo kwaye usigcine kwindawo epholileyo, eyomileyo (2~8℃) kunye nendawo yokugcina impahla engena moya ikude kwizinto ezingahambelaniyo.Khusela ukukhanya kunye nokufuma.
Ukuhambisa ngenqanawe:Zisa kwihlabathi liphela ngomoya, ngeFedEx / DHL Express.Ukubonelela ngokukhawuleza nangokuthembekileyo.
Celecoxib
C17H14F3N3O2S 381.4
4- [5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
p-[5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide [169590-42-5]
INGCACISO
I-Celecoxib iqulethe i-NLT 98.0% kunye ne-NMT 102.0% ye-C17H14F3N3O2S, ibalwe ngokwesiseko se-anhydrous
UKUCHAZA
• A. UFUMBO LWE-INfrared <197>: [QAPHELA-Iindlela <197A>, <197K>, okanye <197M> phantsi kwe-Infrared Absorption zingasetyenziswa.]
[QAPHELA-Ukuba umfanekiso ofunyenweyo ubonisa iyantlukwano, nyibilikisa into eza kujongwa kunye noMgangatho woReferensi ngokwahlukeneyo kwi-isopropyl alcohol, yiba ngumphunga iye kome, kwaye urekhode imbonakalo entsha.]
• B. Ixesha lokugcinwa kwencopho enkulu yesisombululo seSampuli sihambelana nesoMgangatho wesisombululo, njengoko sifunyenwe kwi-Assay.
UVAVANYO
• INKQUBO
Isithinteli: 2.7 g/L ye-monobasic potassium phosphate elungelelaniswe ne-phosphoric acid ukuya kwi-pH ye-3.0 ± 0.2
Inqanaba leselula: Methanol, acetonitrile, kunye neBuffer (3:1:6)
Diluent: Methanol namanzi (3:1)
Isisombululo sokufaneleka kwenkqubo: 0.5 mg / mL ye-USP
Celecoxib RS kunye 2.4 µg/mL nganye USP Celecoxib Related Compound A RS kunye USP Celecoxib Related Compound B RS in Diluent
Isisombululo esisemgangathweni: 0.5 mg / mL ye-USP Celecoxib RS kwi-Diluent
Isisombululo sesampuli: 0.5 mg / mL ye-Celecoxib kwi-Diluent
Inkqubo yeChromatographic
(Jonga iChromatography <621>, Ukufaneleka kweNkqubo.)
Indlela: LC
Umtshina: UV 215 nm
Ikholomu: 4.6-mm × 25-cm;5-µm ukupakisha i-L11
Ubushushu bekholamu: 60 °
Izinga lokuhamba: 1.5 mL / min
Ubungakanani betofu: 25 µL
Ixesha lokubaleka: Malunga ne-1.5 amaxesha encopho ye-celecoxib
Ukufaneleka kwenkqubo
Iisampulu: Isisombululo sokufaneleka kwenkqubo kunye nesisombululo esiPhakathi
Iimfuno zokufaneleka
Isisombululo: I-NLT 1.8 phakathi kwekhompawundi enxulumene ne-celecoxib A kunye ne-Celecoxib kunye ne-NLT 1.8 phakathi kwe-Celecoxib kunye ne-Celecoxib enxulumene nekhompawundi B, isisombululo sokufaneleka kweNkqubo
Ukutenxa komgangatho ozalanayo: NMT 0.73%, isisombululo esisemgangathweni
Uhlalutyo
Iisampulu: Isisombululo esisemgangathweni kunye nesisombululo seSampuli
Bala ipesenti yeC17H14F3N3O2S kwisahlulo seCelecoxib esithathiweyo:
Isiphumo = (rU/rS) × (CS/CU) × 100
rU = impendulo ephezulu evela kwiSampuli yesisombululo
rS = impendulo ephezulu evela kwisisombululo esiPhakathi
CS = ugxininiso lwesisombululo esiPhakathi (mg/mL)
CU = ukuxinana kweSampuli yesisombululo (mg/mL)
Indlela yokwamkela: 98.0% ~ 102.0% kwisiseko se-anhydrous
UBUNGCOLA
Ukungcola Kwezinto Eziphilayo
• IIMETALI EZINZIMA: NMT 20 ppm
Diluent: Iacetone namanzi (17:3)
Isisombululo esisemgangathweni: Nciphisa i-1.0 mL yeSisombululo esiPhambili seNkokheli, elungiselelwe njengoko iqondiswe phantsi kweeNsimbi ezinzima <231>, iiReagents eziKhethekileyo, kunye ne-Diluent kwi-20 mL.
Isisombululo sesampuli: Chitha i-0.50 g ye-Celecoxib kwi-20mL ye-Diluent.
Isisombululo esingenanto: 20 mL yeDiluent
Uhlalutyo
Iisampulu: Isisombululo esisemgangathweni, isisombululo esingenanto, kunye nesisombululo seSampuli
Kwisisombululo ngasinye, yongeza i-2 mL ye-pH 3.5 i-Acetate Buffer elungiselelwe njengoko iqondiswe phantsi kweeMetals eziNzima <231>, Indlela I. Hlanganisa, kwaye ungeze kwisisombululo ngasinye 1.2 mL ye-thioacetamide-glycerin base TS.Hlanganisa ngokukhawuleza, kwaye uvumele ukuma i-2 min.Dlulisa izisombululo kwisihluzo se-0.45-µm yesayizi yepore.Thelekisa amabala kwizihluzi ezifunyenwe kwisicombululo ngasinye.
Iinqobo zokwamkelwa: Umbala omdaka-omnyama webala ophuma kwiSampuli yesisombululo awukho nzulu kunoko webala eliphuma kwisisombululo esiPhakathi.Uvavanyo alusebenzi ukuba isisombululo soMgangatho asibonisi umbala omdaka-mnyama xa kuthelekiswa nesisombululo esingenanto.
• INTSALELA YOKUBASA <281>: NMT 0.2%, kusetyenziswa iplatinam crucible
Ukungcola Okuphilayo
• INKQUBO
I-Buffer, isigaba se-Mobile, i-Diluent, isisombululo sokufaneleka kweSistim, isisombululo seSample, kunye nenkqubo yeChromatographic: Qhubeka njengoko kubhaliwe kwi-Assay.
Isisombululo esisemgangathweni: 0.5 µg/mL ye-USP Celecoxib RS kwiDiluent
Ukufaneleka kwenkqubo
Iisampulu: Isisombululo sokufaneleka kwenkqubo kunye nesisombululo esiPhakathi
Iimfuno zokufaneleka
Isisombululo: I-NLT 1.8 phakathi kwe-Celecoxib enxulumene nekhompawundi A kunye ne-Celecoxib kunye ne-NLT 1.8 phakathi kwe-Celecoxib kunye ne-Celecoxib enxulumene nekhompawundi B, isisombululo sokufaneleka kweNkqubo
Umlinganiselo we-Signal-to-noise: NLT 20, isisombululo esisemgangathweni
Uhlalutyo
Iisampulu: Isisombululo esisemgangathweni kunye nesisombululo seSampuli
Bala ipesenti yokungcola ngakunye kwinxalenye yeCelecoxib ethathiweyo:
Isiphumo = (rU/rS) × (CS/CU) × 100
I-rU = impendulo ephezulu yokungcola ngakunye kwiSampuli isisombululo
rS = impendulo ephezulu ye-celecoxib kwisisombululo esiPhakathi
CS = ukuxinwa kwe-celecoxib kwisisombululo esiPhakathi (mg/mL)
I-CU = i-concentration ye-Celecoxib kwi-Sample solution (mg/mL)
Iinqobo zokwamkelwa
Ukungcola komntu ngamnye: Jonga kwiTheyibhile 1.
[QAPHELA-Ungakhathaleli nayiphi na incopho yokungcola engaphantsi kwe-0.05%.]
Uluhlu loku-1
| Igama | Ixesha lokuGcina isihlobo | Iinqobo zokwamkelwa kwe-NMT (%) |
| Ikhompawundi enxulumene neCelecoxib Aa | 0.9 | 0.4 |
| Celecoxib | 1.0 | - |
| Ikhompawundi enxulumene neCelecoxib Bb | 1.1 | 0.10 |
| Ukungcola komntu ngamnye okungachazwanga | - | 0.10 |
| Ukungcola okupheleleyo | - | 0.5 |
a 4-[5-(3-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
b 4-[3-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
IIMVAVANYO EZITHILE
• UKUMISELWA KWAMANZI, Indlela I <921>: NMT 0.5%, kusetyenziswa isampuli ye-400-mg
IIMFUNO EZONGEZELELWEYO
Ukupakishwa NOKUGCINA: Zigcine kwizikhongozeli eziqinileyo, ezikhuselwe ekukhanyeni nasekufumameni.Gcina kwiqondo lokushisa
• IMIGANGATHO YE-USP REFERENCE <11>
USP Celecoxib RS
p-[5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
C17H14F3N3O2S 381.4
USP Celecoxib Related Compound A RS
4--[5-(3-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
C17H14F3N3O2S 381.4
USP Celecoxib Related Compound B RS
4--[3-(4-Methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.
C17H14F3N3O2S 381.4
Ukuthenga njani?Nceda uqhagamshelaneDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Amava Eminyaka Eli-15?Sineminyaka engaphezu kwe-15 yamava ekwenziweni nasekuthumeleni kumazwe angaphandle uluhlu olubanzi oluphezulu lwamayeza aphakathi okanye amachiza alungileyo.
Iimarike eziphambili?Thengisa kwimarike yasekhaya, eMntla Melika, eYurophu, eIndiya, eKorea, eJapan, eOstreliya, njl.
Iingenelo?Umgangatho ophezulu, ixabiso elifikelelekayo, iinkonzo zengcali kunye nenkxaso yobugcisa, ukuhanjiswa ngokukhawuleza.
UmgangathoIsiqinisekiso?Inkqubo yokulawula umgangatho ongqongqo.Izixhobo zobuchwephesha zokuhlalutya ziquka i-NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, njl.
Iisampulu?Uninzi lweemveliso zibonelela ngeesampulu zasimahla zokuvavanya umgangatho, iindleko zokuthumela kufuneka zihlawulwe ngabathengi.
Factory Audit?Uphicotho-zincwadi lwasefektri wamkelekile.Nceda wenze idinga kwangaphambili.
MOQ?Akukho MOQ.Umyalelo omncinci wamkelekile.
Ixesha lokuzisa? Ukuba ngaphakathi kwesitokhwe, ukuhanjiswa kweentsuku ezintathu kuqinisekisiwe.
Ezothutho?Nge-Express (FedEx, DHL), ngoMoya, ngoLwandle.
Amaxwebhu?Emva kwenkonzo yokuthengisa: I-COA, i-MOA, i-ROS, i-MSDS, njl.
Udibaniso lweSiko?Inokubonelela ngeenkonzo zesiko lokudibanisa ukuze zilungele iimfuno zakho zophando.
Immimiselo yokuhlawula?I-invoyisi yeProforma iya kuthunyelwa kuqala emva kokuqinisekiswa kwe-odolo, efakwe kwiinkcukacha zethu zebhanki.Intlawulo nge-T / T (i-Telex Transfer), i-PayPal, i-Western Union, njl.
| Iimpawu ezinobungozi | Xn - Inobungozi |
| Iikhowudi zoMngcipheko | I-R20/21/22 - Iyingozi ngokuphefumla, xa udibana nolusu naxa uginyiwe. |
| I-R52 - Iyingozi kwizinto eziphila emanzini | |
| I-R61 - Inokubangela ingozi kumntwana ongekazalwa | |
| I-R60 - Ingaphazamisa ukuchuma | |
| Inkcazelo yoKhuseleko | S22 - Musa ukuphefumla uthuli. |
| I-S24/25 - Gwema ukudibana nolusu kunye namehlo. | |
| S28 - Emva kokudibana nolusu, hlamba ngoko nangoko ngeesepha ezininzi. | |
| I-S37/39 - Nxiba iiglavu ezifanelekileyo kunye nokukhusela amehlo / ubuso | |
| Izazisi ze-UN | UN 3077 9 / PGIII |
| WGK eJamani | 3 |
| RTECS | DB2944937 |
| Ikhowudi ye-HS | 2935900090 |
| IKlasi yeeNgozi | OKUTHUTHUKILEYO |
I-Celecoxib kunye ne-Rofecoxib zimbini ezisetyenziswa ngoku i-COX-2 inhibitors.Iphuhliswe ngempumelelo nguGD Searle & Pfizer Co. (US,) ekhutshwe kwi-1999, igama lokurhweba: Celebrex.I-Celecoxib i-nonsteroidal, i-anti-inflammatory agent ene-analgesic ebalulekileyo kunye ne-anti-inflammatory effects, ebangela iziganeko ezisezantsi zezilonda ze-gastrointestinal tract kunye nezinye iingxaki.Isetyenziswa eklinikhi ukunyanga i-osteoarthritis ebukhali kwaye engapheliyo kunye ne-rheumatoid arthritis, kunye nendima ye-anti-inflammatory analgesic, ukukhulula iimpawu kunye neempawu ze-osteoarthritis kunye ne-rheumatoid arthritis.
I-Celecoxib (CAS: 169590-42-5), Uncedo kunye nolawulo lwe-osteoarthritis (OA), i-rheumatoid arthritis (RA), i-arthritis ye-juvenile rheumatoid (JRA), i-ankylosing spondylitis, iintlungu ezibuhlungu, i-dysmenorrhea yokuqala kunye ne-adjunct yomlomo kukhathalelo oluqhelekileyo lwezigulane. kunye ne-familial adenomatous polyposis.
I-Celecoxib (i-CAS: 169590-42-5) ine-anti-inflammatory kunye ne-analgesic effect ye-NSAIDs.Ngenxa yobume bayo beekhemikhali, inokudibaniswa ne-COX-2, inqande ngokukhetha i-COX-2.Iqela layo le-phenyl libophelela ngejelo le-hydrophobic ye-COX-2, kwaye i-hydrophilic sulfonamide yayo yenza ikhonkco le-hydrogen kunye ne-513 arginine kunye ne-90 histidine kwi-COX-2 "ipokotho esecaleni."Ikwanxibelelana ngokusondeleyo ne-arginine kwindawo ye-COX-2120 kwaye idlala indima ekunqandeni i-COX-2 ekuguquleni i-arachidonic acid ibe yi-prostaglandins eyingozi kumzimba womntu.Ngenxa yomahluko ofihlakeleyo phakathi kwezakhiwo ze-COX-1 kunye ne-COX -2, i-Celecoxib ayikwazi ukungena kwi-molecule ye-COX-1, okanye inqanda ukuguqulwa kwayo kwe-arachidonic acid kwi-prostaglandins, ngoko, ineempembelelo ezintle ezichasayo kunye ne-analgesic, ikhusela i-gastric mucosa, ikhusela ukuhamba kwegazi kwezintso, ilawula ukuhlanganiswa kweplatelet, kwaye isombulule i-aggregation. iingxaki zokucaphuka kwesisu kwii-NSAID ezisetyenziswa ngokuqhelekileyo.
I-Celecoxib (i-CAS: i-169590-42-5) iboniswa kunyango lwe-osteoarthritis kunye ne-rheumatoid arthritis.Ukusetyenziswa kwayo kunqatshelwe kubantu abane-hypersensitivity kwi-sulfonamides okanye ezinye ii-NSAID.Kufuneka isetyenziswe ngononophelo kubantu abanesifo sesibindi.Ukudibana kwenzeka namanye amachiza adala iCYP2C9 (umz. rifampin rifampin) okanye akhuphisane ngemetabolism ngale enzyme (umz. fluconazole, leflunomide).Ezona mpendulo zixhaphakileyo zixhaphakileyo kwi-celecoxib zinobulali ukuya kwimodareyitha iziphumo ze-GI ezifana ne-dyspepsia, urhudo, kunye neentlungu zesisu.I-GI enzima kunye neziphumo ze-renal zenzeke ngokungaqhelekanga.
